The Journal of Antibiotics (2026) 79:402–409 https://doi.org/10.1038/s41429-026-00919-x ARTICLE Comparative activity of sulbactam and sulbactam/durlobactam against carbapenem-resistant A. baumannii isolates producing OXA23 or OXA-23 plus PER-1 enzymes Hasan Cenk Mirza1 Aylin Üsküdar Güçlü1 Sezin Ünlü1 Süleyman Yalçın2 ● ● ● 1234567890();,: 1234567890();,: Received: 29 July 2025 / Revised: 4 February 2026 / Accepted: 18 March 2026 / Published online: 10 April 2026 © The Author(s) 2026. This article is published with open access Abstract Our objective was to compare the in vitro activity of sulbactam and sulbactam/durlobactam against carbapenem-resistant A. baumannii isolates carrying blaOXA−23 or both blaOXA−23 and blaPER-1 genes. We also aimed to investigate the possible mechanisms of resistance in sulbactam/durlobactam resistant isolates. Twenty-four carbapenem-resistant A. baumannii isolates (12 carrying blaOXA−23, 12 carrying blaOXA−23 and blaPER-1) were included in the study. Genetic relations among isolates were determined by Pulsed-Field Gel Electrophoresis (PFGE). MICs of sulbactam and sulbactam/durlobactam were determined by gradient diffusion method. Whole-genome sequencing was performed on sulbactam/durlobactam resistant isolates. Among 24 isolates, PFGE revealed 5 distinct major clusters. One (4.2%) and 22 (91.7%) of isolates were susceptible to sulbactam and sulbactam/durlobactam, respectively. Sulbactam MIC50 value for isolates carrying blaOXA−23 plus blaPER-1 (32 mg/L) were 2.7 fold higher than that for isolates carrying blaOXA−23 (12 mg/L). However, similar sulbactam/durlobactam MIC50 values were observed for isolates carrying blaOXA−23 plus blaPER-1 (1 mg/L) or blaOXA−23 (1.5 mg/L). Both the two sulbactam/durlobactam resistant isolates had mutations in PBP3 gene. The isolate with sulbactam/ durlobactam MIC of 12 mg/L had A515V and C1546T mutations in PBP3 gene. Also, the AdeN (repressor of AdeIJK efflux system) was absent in this isolate. The isolate with sulbactam/durlobactam MIC of >64 mg/L had one amino acid insertion at position 374 (-374D) in PBP3. Sulbactam/durlobactam demonstrated high activity against carbapenem-resistant A. baumannii isolates. Sulbactam/durlobactam resistance was likely due to mutations in PBP3 gene. Overexpression of AdeIJK efflux system may also have contributed to resistance in one isolate. Introduction In May 2024, the World Health Organization (WHO) updated its list of antibiotic-resistant bacteria which pose the greatest threat to human health. Carbapenem-resistant Acinetobacter baumannii is still included in the critical priority category of list [1]. Most of the antibiotics are ineffective against infections caused by carbapenemresistant A. baumannii, emphasizing the need for * Hasan Cenk Mirza h_cenkmirza@yahoo.com.tr 1 Department of Medical Microbiology, Başkent University Faculty of Medicine, Ankara, Türkiye 2 Ministry of Health, General Directorate of Public Health, Microbiology Reference Laboratory, Ankara, Türkiye development of new antibiotics against this opportunistic pathogen [2]. The main mechanism responsible for carbapenem resistance in A. baumannii is the production of class D β-lactamases; primarily the OXA-23, OXA-58 and OXA-24/40 [3]. Resistance in A. baumannii to broad-spectrum cephalosporins is predominantly due to the overexpression of the AmpC β-lactamases or production of extended-spectrum βlactamases (ESBL) [4]. PER-1 β-lactamase is an ESBL enzyme belong to Ambler class A and was first detected in a Pseudomonas aeruginosa isolated from a Turkish patient in France in 1993. Later, PER enzymes were also reported in Acinetobacter isolates from different parts of the world including Türkiye, South Korea, France, Belgium, China, India, Iran, Saudi Arabia, Tunisia and Argentina [5, 6]. Sulbactam is a first-generation β-lactamase inhibitor which has limited activity against Ambler class A serine βlactamases [3]. In addition, sulbactam has intrinsic activity against A. baumannii, due to the inhibiton of cell wall Comparative activity of sulbactam and sulbactam/durlobactam against carbapenem-resistant A. baumannii. . . synthesis by binding to penicillin-binding proteins (PBPs) including PBP1a, PBP1b and PBP3 [7, 8]. However, susceptibility of sulbactam to degradation by various βlactamases found in many Acinetobacter spp. isolates limits its use in infections caused by this microorganism [9]. Durlobactam is a novel non-β-lactam β-lactamase inhibitor which inhibits Ambler class A, C and D β-lactamases [10, 11]. In 2023, durlobactam in combination with sulbactam was approved by the US Food and Drug Administration (FDA) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by Acinetobacter baumanniicalcoaceticus complex [12]. The sulbactam/durlobactam zone diameter and MIC breakpoints assigned by FDA were also approved by CLSI in 2023 and were published in the 34th edition of CLSI M100 document in 2024 [13]. Our objective was to investigate the in vitro activity of sulbactam and sulbactam/durlobactam against a collection of carbapenem-resistant A. baumannii isolates including strains carrying blaOXA−23 gene or carrying both blaOXA−23 and blaPER-1 genes. We also aimed to investigate the mechanisms responsible for sulbactam/durlobactam resistance among A. baumannii isolates. Materials and methods This study was approved by Başkent University Institutional Review Board (Project no: DA24/07) and supported by Başkent University Research Fund. Bacterial isolates A total of 24 clinical isolates of carbapenem-resistant A. baumannii including strains carrying blaOXA−23 (n = 12) or carrying both blaOXA−23 and blaPER-1 (n = 12) were included in the study. Strains were randomly selected from a collection of A. baumannii clinical isolates those were characterized in our previous study and stored at Medical Microbiology Laboratory of Başkent University Medical Faculty [14]. Strains were isolated in 2020 and 2021. One isolate per patient was included. Isolates were obtained from blood (n = 12), tracheal aspirate (n = 11), and bronchoalveolar lavage (n = 1). Antimicrobial susceptibility testing MICs of sulbactam and sulbactam/durlobactam were determined with gradient diffusion method using sulbactam MIC test strips (Liofilchem, Roseto degli Abruzzi, Italy) and sulbactam/durlobactam Etest strips (bioMérieux; Marcy-l'Étoile, France). Sulbactam/durlobactam Etest strips were provided by International Health Management 403 Associates (IHMA) within the scope of the Antimicrobial Voluntary Evaluation Program (AVEP). To determine the MICs for isolates, the bacterial suspension equal to the turbidity of 0.5 McFarland standard was swabbed onto Mueller–Hinton agar (Condalab, Madrid, Spain) and allowed to dry. Afterwards, strips containing sulbactam and sulbactam/durlobactam were placed on the surface of agar and the plates were incubated at 35 °C for 16–20 h. CLSI and EUCAST have not provided sulbactam MIC breakpoints for Acinetobacter spp. yet. However, CLSI provides ampicillin/sulbactam MIC breakpoints (susceptible ≤8/4 mg/L, intermediate 16/8 mg/L and resistant ≥32/16 mg/ L) for Acinetobacter spp. As the sulbactam comprises the active component of the combination, sulbactam MIC breakpoints of ≤4 mg/L (susceptible), 8 mg/L (intermediate) and ≥16 mg/L (resistant) were used [8, 15]. Sulbactam/ durlobactam MICs were interpreted according to CLSI criteria in M100-S34 (susceptible ≤4/4 mg/L, intermediate 8/4 mg/L and resistant ≥16/4 mg/L) [15]. A. baumannii NCTC 13304 was used as quality control strain. Pulsed-field gel electrophoresis (PFGE) Genetic relations among carbapenem-resistant A. baumannii clinical isolates were determined by PFGE according to the protocol described by Gouby et al. [16]. Genomic DNA was lysed with lysis solutions and digested with ApaI restriction enzyme (Takara, Japan). Electrophoresis was performed in a pulsed-field electrophoresis system (CHEF-DR III System; Bio-Rad, USA). Cluster analysis was performed using BioNumerics software. Isolates were defined as closely related if they differ by ≤3 bands and possibly related if they differ by 4–6 bands, according to criteria of Tenover et al. [17]. Whole-genome sequencing and analysis To understand the molecular drivers of resistance against sulbactam/durlobactam, all sulbactam/durlobactam resistant isolates were subjected to whole-genome sequencing (WGS) and analyzed for β -lactamase gene content, and variations in PBPs and AdeIJK efflux system. Variations in the AdeIJK efflux system was reported to play role in sulbactam/durlobactam resistance in some Acinetobacter spp. isolates [9]. Whole-genome sequencing of a sulbactam/durlobactam susceptible isolate was also performed for comparison. Genomic DNA extraction of bacterial isolates were performed by using EZ1 automated sample purification system (Qiagen, Germany). DNA was quantified by Qubit 4 fluorometer. The whole genome was sequenced by Oxford Nanopore prometION sequencing system (ONT, Oxford, UK). Libraries were prepared using the Native Barcoding Kit. De novo assemblies of the genomes were generated using flye v. 404 Table 1 Sulbactam and sulbactam/durlobactam susceptibilities of isolates carrying blaOXA−23 or both blaOXA−23 and blaPER-1 genes H. C. Mirza et al. β-lactamase genes Sulbactam Sulbactam/Durlobactam MIC (mg/L) %S/%I/%R MIC (mg/L) 50% 90% Range blaOXA−23 (n = 12) 12 32 4–>256 blaOXA−23 + blaPER-1 (n = 12) (n = 12) 32 192 Total 24 192 50% 90% Range 8.3/16.7/ 75.0 %S/%I/% R 1.5 12 0.75–>64 83.3/0/ 16.7 24–>256 0/0/100 1 2 0.75–2 4–>256 1,5 2 0.75–>64 91.7/0/8.3 4.2/8.3/ 87.5 100/0/0 Fig. 1 Gradient diffusion test results for two sulbactam/durlobactamresistant isolates. A No zone of inhibiton was observed for the isolate Ab19 which indicates high level (MIC > 64 mg/L) sulbactam/durlobactam resistance. B Isolate Ab92 exhibited some small colonies within the inhibiton zone and categorized as resistant to sulbactam/ durlobactam. C Magnified appearance of (B). Isolate Ab92 had sulbactam/durlobactam MIC of 12 mg/L (resistant) 2.9.3. For the quality of the genome assemblies and trimming, Fastqc v.0.12.1 and Porechop v.0.2.4 were used [18, 19]. The assembled genomes were annotated with RasTK [20] and PROKKA [21]. According to functional gene annotation; PBP1a, PBP1b, PBP3 and efflux pump regions were alligned with the A. baumannii ATCC 17978 (GenBank accession number CP018664.1) to detect the mutations by using MEGAX [22]. The existence of β-lactamese encoding genes in the genome was investigated via ResFinder 4.0 [23]. (91.7%) of 24 isolates were susceptible to sulbactam/durlobactam (Table 1). Adding durlobactam to sulbactam restored sulbactam susceptibility in 21 (91.3%) of 23 sulbactam-non-susceptible isolates. The two sulbactam/ durlobactam resistant isolates had sulbactam/durlobactam MICs of >64 mg/L and 12 mg/L, respectively (Fig. 1). The isolate with high level resistance to sulbactam/durlobactam (MIC > 64 mg/L) was also highly resistant (MIC > 256 mg/ L) to sulbactam. The isolate with sulbactam/durlobactam MIC of 12 mg/L had sulbactam MIC of 24 mg/L. Two sulbactam/durlobactam resistant isolates were positive for blaOXA−23 but negative for blaPER-1 (Table 2). Among 24 carbapenem-resistant isolates, 3 were also found to be resistant to colistin with commercial broth microdilution plate (Sensititre FRCOL plate, Thermo Fisher Scientific, USA). However, two sulbactam/durlobactam resistant isolates were susceptible to colistin. The sulbactam MICs for isolates carrying blaOXA −23+blaPER-1 were significantly higher than those for the isolates carrying blaOXA−23 (p = 0.003). However no statistically significant difference was found between sulbactam/durlobactam MICs for isolates carrying blaOXA −23+blaPER-1 and isolates carrying blaOXA−23 (p = 0.061). The sulbactam MIC50 value for isolates carrying blaOXA−23 plus blaPER-1 (32 mg/L) were 2.7 fold higher than that for the isolates carrying blaOXA−23 (12 mg/L). However, similar Statistical analysis The Mann-Whitney U Test was used to compare sulbactam MICs for ‘blaOXA−23 carrying’ and ‘blaOXA−23+bla PER-1 carrying’ isolates. The same test was also used to compare sulbactam/durlobactam MICs for ‘blaOXA−23 carrying’ and ‘blaOXA−23+bla PER-1 carrying’ isolates. The Wilcoxon Signed-Rank Test was used to compare sulbactam and sulbactam/durlobactam MICs for A. baumannii isolates. P values of <0.05 were considered statistically significant. Results Among 24 carbapenem-resistant A. baumannii isolates, only one (4.2%) was susceptible to sulbactam. However, 22 Comparative activity of sulbactam and sulbactam/durlobactam against carbapenem-resistant A. baumannii. . . 405 Table 2 Sulbactam, sulbactam/durlobactam MIC values and sources of 24 A. baumannii isolates, and demographic information of patients Isolate no Patient age/gender Ward Source β-lactamases Sulbactam Sulbactam/durlobactam MIC (mg/L) Category MIC (mg/L) Category Ab6 78/M ICU Tracheal aspirate OXA-23 4 S 1.5 S Ab8 80/M ICU BAL OXA-23 12 R 0.75 S Ab19 75/F ICU Tracheal aspirate OXA-23 >256 R >64 R Ab21 79/M ICU Blood OXA-23 12 R 2 S Ab29 61/F OG Blood OXA-23 12 R 1 S Ab32 75/M TS Tracheal aspirate OXA-23 12 R 1 S Ab41 94/F CD Blood OXA-23 32 R 1.5 S Ab44 67/M Neurosurgery Tracheal aspirate OXA-23 8 I 2 S Ab49 62/M GS Blood OXA-23 24 R 1.5 S Ab55 76/F ICU Tracheal aspirate OXA-23 6 I 2 S Ab70 73/F ICU Blood OXA-23 12 R 2 S Ab92 45/F ICU Blood OXA-23 24 R 12 R Ab1 53/M ICU Blood OXA-23 + PER-1 48 R 1.5 S Ab10 47/M ICU Blood OXA-23 + PER-1 192 R 2 S Ab15 25/M BCU Blood OXA-23 + PER-1 32 R 1 S Ab27 68/M ICU Tracheal aspirate OXA-23 + PER-1 64 R 0.75 S Ab28 28/F ICU Blood OXA-23 + PER-1 64 R 1 S Ab36 81/M ICU Tracheal aspirate OXA-23 + PER-1 >256 R 2 S Ab38 65/M ICU Tracheal aspirate OXA-23 + PER-1 24 R 1.5 S Ab46 87/F Rheumatology Blood OXA-23 + PER-1 24 R 1 S Ab51 57/M ICU Tracheal aspirate OXA-23 + PER-1 32 R 1.5 S Ab58 4/M CVS Tracheal aspirate OXA-23 + PER-1 32 R 0.75 S Ab78 79/F Neurosurgery Blood OXA-23 + PER-1 24 R 1 S Ab90 4 months/M CVS Tracheal aspirate OXA-23 + PER-1 24 R 1 S BAL bronchoalveolar lavage, BCU burn care unit, CD chest diseases, CVS cardiovascular surgery, F female, GS general surgery, ICU intensive care unit, I intermediate, M male, OG obstetrics and gynecology, R resistant, S susceptible, TS thoracic surgery sulbactam/durlobactam MIC50 values were observed for the isolates carrying blaOXA−23 plus blaPER-1 (1 mg/L) and the isolates carrying blaOXA−23 (1.5 mg/L) (Table 1). Considering a total of 24 isolates, the addition of durlobactam decreased the sulbactam MIC50 value by 16-fold (from 24 to 1.5 mg/L) and sulbactam MIC90 value by 96fold (from 192 to 2 mg/L) (Table 1). The sulbactam/durlobactam MICs were significantly lower than sulbactam MICs (p < 0.001). Among 24 isolates, PFGE revealed 5 distinct major clusters. The largest cluster contained 9 isolates, while the second and third largest clusters had 4 and 7 isolates, respectively. The smaller cluster contained 3 isolates. One isolate (Ab6) had a unique banding pattern compared to the other isolates, forming a distinct, unrelated lineage (Fig. 2). To understand the molecular mechanisms responsible for sulbactam/durlobactam resistance, two sulbactam/durlobactam-resistant isolates were subjected to whole-genome sequencing. In addition, one randomly selected sulbactam/ durlobactam susceptible isolate was subjected to wholegenome sequencing for comparison. All the three isolates (two sulbactam/durlobactam resistant and one suceptible) carried inherent beta-lactamase genes for A. baumannii, blaOXA-66(blaOXA-51-like gene) and blaADC. In addition, whole-genome sequencing analysis showed the presence of blaTEM in one of the sulbactam/ durlobactam resistant isolates. In both of the two sulbactam/durlobactam resistant isolates, mutations were observed in the genes encoding PBP3. The isolate with sulbactam/durlobactam MIC of 12 mg/L had A515V and C1546T mutations in the PBP3 gene. The isolate with sulbactam/durlobactam MIC of >64 mg/L had one amino acid insertion at position 374 (-374D) in PBP3. In addition to these mutations, both sulbactam/durlobactam resistant isolates encoded three silent mutations (C780T, A906G and A1568T) in PBP3 gene. In sulbactam/ 406 H. C. Mirza et al. Fig. 2 Dendrogram of pulsedfield gel electrophoresis (PFGE) cluster analysis of 24 A. baumannii isolates from different patients. Five clusters were found according to banding patterns of each isolate durlobactam resistant strains, no mutations were detected in the genes encoding PBP1a and PBP1b, the other targets of sulbactam. Regarding efflux systems, the AdeN (the repressor of AdeIJK efflux system) was absent in the isolate with sulbactam/durlobactam MIC of 12 mg/L (Table 3). Discussion To our knowledge, this is the first study to evaluate the activity of sulbactam/durlobactam against A. baumanni isolates in Türkiye. In this study, the in vitro activity of sulbactam/durlobactam was also compared with that of Comparative activity of sulbactam and sulbactam/durlobactam against carbapenem-resistant A. baumannii. . . Table 3 Analysis of penicillinbinding proteins, β-lactamase genes and AdeIJK efflux system in sulbactam/durlobactam resistant (n = 2) and susceptible (n = 1) isolates after wholegenome sequencing 407 Isolates Ab92 Ab19 Ab41 Sulbactam/durlobactam MIC (mg/L) 12 (R) >64 (R) 1.5 (S) Genbank accession number PQ382893 PQ382891 PQ382892 Sequence type 218, 2164 1697, 2535 502 Amino acid sequence length of PBP3 610 611 610 PBP3 A515V C1546T Silent mutations: C780T A906G A1568T -374D (one amino acid insertion at position 374) Silent mutations: C780T A906G A1568T V595L PBP1a Identical Identical Identical PBP1b Identical Identical Identical AdeIJK efflux system AdeN was absent No mutation No mutation β-lactamase genes blaOXA-23, blaTEM-1, blaOXA-66, blaADC-73 blaOXA-23, blaOXA-66, blaADC-30 blaOXA-23, blaPER-1, blaOXA-66, blaADC-25 R resistant, S susceptible sulbactam, and the possible mechanisms of resistance in sulbactam/durlobactam resistant isolates were investigated. The sulbactam MICs for isolates carrying blaOXA−23 plus blaPER-1 were higher than those observed for isolates carrying blaOXA−23 (Table 2). Sulbactam is not an inhibitor of OXA-23 [24]. Instead, it is susceptible to hydrolysis by OXA-23 enzyme, as sulbactam is a β-lactam itself [25]. On the other hand, sulbactam is known to be both a substrate and inhibitor of serine β-lactamases [25] including the ESBL enzyme PER-1 [26]. It was reported that many sulbactam molecules are needed to inactivate a single molecule of a serine β-lactamase. For example, the TEM-1 β-lactamase first hydrolyses ~7000 molecules of sulbactam and then sulbactam functions as an inhibitor of enzyme [27]. Although we could not find a data regarding the number of sulbactam molecules to inactivate PER-1 enzyme, it is likely that large quantities of sulbactam molecules are used for the inactivation of PER-1. Thus, in isolates carrying blaOXA−23 plus blaPER-1, lower number of free sulbactam molecules available for the inhibition of PBPs may be the cause of increased sulbactam MICs when compared with isolates that do not carry blaPER-1. In a systematic review, the molecular epidemiology of carbapenem-resistant A. baumannii isolates in Türkiye was evaluated by analyzing original research articles published between January 2010 and January 2022 [28]. The incidence rates of carbapenemase genes blaOXA−23 and blaOXA−58 in carbapenem-resistant A. baumannii isolates were reported as 76.4% and 8.4%, respectively. Also, the prevalences of both these genes increased with time. The average positivity rates of blaNDM and the ESBL gene blaPER-1 was reported as 0.1% and 9.7%, respectively [28]. The strains in our study was isolated in 2020 and 2021. The prevalence of OXA-type carbapenemases in A. baumannii may have increased from 2020 to 2026. Despite a possible increase in the prevalence of OXA-type carbapenemases, sulbactam/durlobactam may still show high activity against carbapenem-resistant A. baumannii isolates as durlobactam is an inhibitor of Ambler class D β-lactamases. However, it is unknown whether the PBP3 mutation patterns or the prevalence of isolates with PBP3 mutations have changed in Türkiye over time. Changes regarding PBP3 may directly influence the activity of sulbactam/durlobactam and may limit the generalizability of our findings from earlier isolates. In sulbactam/durlobactam combination, sulbactam is known to be the active component against Acinetobacter spp. Durlobactam is reported to have no intrinsic activity against A. baumannii [11]. Durlobactam protects sulbactam from hydrolysis by β-lactamase enzymes. However it does not inhibit metallo-β-lactamases. For the two sulbactam/ durlobactam resistant isolates in our study, β-lactamases likely had very limited effect on sulbactam and sulbactam/ durlobactam resistance and other factors were present; because adding durlobactam to sulbactam did not restore sulbactam susceptibility and these isolates did not carry metallo-β-lactamase genes. In one of the isolates, the addition of durlobactam led to a very limited reduction in sulbactam MIC value (from 24 to 12 mg/L). The isolate with high level sulbactam resistance (MIC > 256 MIC mg/ L) still exhibited high level resistance (MIC > 64 mg/L) after the addition of durlobactam. In both of the isolates, mutations in PBP3 gene were detected. The first isolate 408 encoded the A515V variant of PBP3 gene. A515V substitution was reported to be associated with sulbactam/ durlobactam resistance [7]. However, some authors suggest that A515V substitution is not sufficient to confer sulbactam/durlobactam resistance and additional factors are probably needed [9]. The first isolate had an additional mutation (C1546T) in PBP3 gene. Furthermore, the AdeN (the repressor of AdeIJK efflux system) was absent in this isolate. Durlobactam was reported to be a substrate for the AdeIJK efflux system [9]. The overexpression of this efflux system and the additional mutation in PBP3 gene may also have contributed to sulbactam/durlobactam resistance. In the second isolate, insertion of an additional amino acid at position 374 (-374D) in PBP3 was detected. Unlike A515V and C1546T, this mutation may be associated with high-level resistance to sulbactam and sulbactam/durlobactam because this isolate had sulbactam MIC of >256 MIC mg/L and sulbactam/durlobactam MIC of >64 mg/L. This mutation may have caused a substantial reduction in the affinity of PBP3 for sulbactam. In our study, sulbactam/durlobactam resistant isolates were also found to encode three silent mutations in PBP3 gene. A silent mutation alters the nucleotide sequence but not the amino acid sequence. The effect of silent mutations has traditionally been considered to be either neutral or nearly neutral. However, recent evidence has demonstrated that they can affect protein levels or conformation [29]. Although we included a small number of isolates in our study, it may be useful to indicate the sulbactam/durlobactam susceptibility rate (91.7%). In a study including 5032 clinical isolates of A. baumannii-calcoaceticus complex from 33 countries, sulbactam/durlobactam MIC values for 98.3% of isolates were ≤4 mg/L (susceptible) [8]. In another study including 1722 clinical isolates of A. baumannii-calcoaceticus complex from 31 countries, 97.7% of isolates had sulbactam/durlobactam MIC of ≤4 mg/L [11]. However, the collections in these two studies comprised both carbapenem-susceptible and carbapenemresistant isolates [8, 11]. In the study conducted by Seifert et al., 237 (96.3%) of 246 carbapenem-resistant A. baumannii isolates from 37 countries had sulbactam/durlobactam MIC of ≤4 mg/L [30]. The sulbactam/durlobactam susceptibility rate in our set of isolates (91.7%) was similar to that reported by Segatore et al. (92.2%) who evaluated the in vitro activity of the sulbactam/durlobactam against 141 carbapenem-resistant A. baumannii isolates collected from six clinical microbiology laboratories in Italy [31]. Studies which report lower sulbactam/durlobactam susceptibility rates (below 90%) among carbapenem-resistant A. baumannii isolates also exist. Petropoulou et al. tested the in vitro activity of sulbactam/durlobactam against 190 carbapenem-resistant A. baumannii isolates collected from H. C. Mirza et al. 11 hospitals throughout Greece and found a susceptibility rate of 87.9% [3]. This study has some limitations. First, we used gradient diffusion method instead of the reference broth microdilution method for the determination of sulbactam and sulbactam/durlobactam MICs. Broth microdilution is known to provide more reliable and accurate results when compared to gradient diffusion method. Second, sulbactam breakpoints for A. baumannii have not been formally established by CLSI or EUCAST. As sulbactam is known to be the active component of ampicillin/sulbactam combination against Acinetobacter spp., we used the susceptibility breakpoint of 4 mg/L for sulbactam, based on the ampicillin/sulbactam susceptibility breakpoint of 8/4 mg/L established by the CLSI. Although several studies adopted this approach, using a surrogate breakpoint may influence the interpretation of comparative activities of sulbactam and sulbactam/durlobactam against isolates [8, 31, 32]. Third, we could not include detailed clinical information regarding patients because we couldn’t access the complete medical records of patients. In conclusion, sulbactam/durlobactam demonstrated high activity against carbapenem-resistant A. baumannii strains in our study and restored sulbactam susceptibility in ~90% of sulbactam-non-susceptible isolates. Presence of blaPER-1 in addition to blaOXA−23 led to an increase in sulbactam MICs but not in sulbactam/durlobactam MICs. Mutations observed in the PBP3 gene of sulbactam/durlobactam resistant isolates may have led to the development of resistance by reducing affinity of PBP3 for sulbactam. Also, lack of the repressor of AdeIJK efflux system in one of the resistant isolates may have contributed sulbactam/durlobactam resistance by causing the overexpression of efflux pumps. Data availability Sequence data that support the findings of this study have been deposited in GenBank of National Library of Medicine (https://www.ncbi.nlm.nih.gov/) with the accession numbers of PQ382891, PQ382892, and PQ382893. Acknowledgements We thank International Health Management Associates (IHMA) for providing sulbactam/durlobactam Etest strips. We thank Caner İncekaş for statistical analysis. Funding This study was and supported by Başkent University Research Fund. Open access funding provided by the Scientific and Technological Research Council of Türkiye (TÜBİTAK). Compliance with ethical standards Conflict of interest The authors declare no competing interests. Comparative activity of sulbactam and sulbactam/durlobactam against carbapenem-resistant A. baumannii. . . Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons. org/licenses/by/4.0/. References 1. WHO: Bacterial Priority Pathogens List. 2024. https://iris.who.int/ server/api/core/bitstreams/1a41ef7e-dd24-4ce6-a9a61573562e7f37/content. 2. Penwell WF, et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59:1680–9. 3. Petropoulou D, Siopi M, Vourli S, Pournaras S. Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece. Front Cell Infect Microbiol. 2022;11:814530. 4. Bonnin RA, et al. PER-7, an extended-spectrum beta-lactamase with increased activity toward broad-spectrum cephalosporins in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55:2424–7. 5. Aly MM, Abu Alsoud NM, Elrobh MS, Al Johani SM, Balkhy HH. High prevalence of the PER-1 gene among carbapenemresistant Acinetobacter baumannii in Riyadh, Saudi Arabia. Eur J Clin Microbiol Infect Dis. 2016;35:1759–66. 6. Mabrouk A, et al. Clonal spread of PER-1 and OXA-23 producing extensively drug resistant Acinetobacter baumannii during an outbreak in a burn intensive care unit in Tunisia. Acta Microbiol Immunol Hung. 2020;67:222–7. 7. Findlay J, Poirel L, Bouvier M, Nordmann P. In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance. J Glob Antimicrob Resist. 2022;30:445–50. 8. Karlowsky JA, Hackel MA, McLeod SM, Miller AA. In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021. Antimicrob Agents Chemother. 2022;66:e0078122. 9. Moussa SH, et al. Molecular drivers of resistance to sulbactamdurlobactam in contemporary clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2023;67:e0066523. 10. El-Ghali A, Kunz Coyne AJ, Caniff K, Bleick C, Rybak MJ. Sulbactam-durlobactam: a novel β-lactam-β-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections. Pharmacotherapy. 2023;43:502–13. 11. McLeod SM, Moussa SH, Hackel MA, Miller AA. In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally in 2016 and 2017. Antimicrob Agents Chemother. 2020;64:e02534-19. 12. Entasis Therapeutics. 2023 XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use. Full 409 prescribing information. 2023. https://www.accessdata.fda.gov/ drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf. 13. CLSI. AST News Update January 2024: Sulbactam-Durlobactam: The “double beta-lactamase inhibitor” drug. 2024. https://clsi. org/about/news/ast-news-update-january-2024-sulbactam-durloba ctam-the-double-beta-lactamase-inhibitor-drug/. 14. Uskudar-Guclu A, Danyildiz S, Mirza HC, Akcil Ok M, Basustaoglu A. In vitro activity of cefiderocol against carbapenemresistant Acinetobacter baumannii carrying various β-lactamase encoding genes. Eur J Clin Microbiol Infect Dis. 2024;43:1171–9. 15. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, M100, 34th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2024. 16. Gouby A, et al. Use of pulsed-field gel electrophoresis for investigation of hospital outbreaks of Acinetobacter baumannii. J Clin Microbiol. 1992;30:1588–91. 17. Tenover FC, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233–9. 18. Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010. https://www.bioinformatics.babraham.ac.uk/ projects/fastqc/. 19. Wick RR Porechop. GitHub repository. 2017. https://github.com/ rrwick/Porechop. 20. Brettin T, et al. RASTtk: a modular and extensible implementation of the RAST algorithm for building custom annotation pipelines and annotating batches of genomes. Sci Rep. 2015;5:8365. 21. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30:2068–9. 22. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol. 2018;35:1547–9. 23. Bortolaia V, et al. ResFinder 4.0 for predictions of phenotypes from genotypes. J Antimicrob Chemother. 2020;75:3491–500. 24. Yang Y, et al. OXA-23 is a prevalent mechanism contributing to sulbactam resistance in diverse Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother. 2018;63:e01676–18. 25. Shapiro AB. Kinetics of sulbactam hydrolysis by β-lactamases, and kinetics of β-lactamase inhibition by sulbactam. Antimicrob Agents Chemother. 2017;61:e01612–17. 26. Castanheira M, Simner PJ, Bradford PA. Extended-spectrum βlactamases: an update on their characteristics, epidemiology and detection. JAC Antimicrob Resist. 2021;3:dlab092. 27. Krizova L, Poirel L, Nordmann P, Nemec A. TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii. J Antimicrob Chemother. 2013;68:2786–91. 28. Kilbas EPK, Kilbas I, Ciftci IH. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii isolates in Turkiye: systematic review. North Clin Istanb. 2023;10:531–9. 29. Kikutake C, Suyama M. Possible involvement of silent mutations in cancer pathogenesis and evolution. Sci Rep. 2023;13:7593. 30. Seifert H, et al. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2020;75:2616–21. 31. Segatore B, et al. In vitro activity of Sulbactam-Durlobactam against carbapenem-resistant Acinetobacter baumannii clinical isolates: a multicentre report from Italy. Antibiotics. 2022;11:1136. 32. Buyukyanbolu E, et al. Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against Acinetobacter baumannii-calcoaceticus complex strains isolated from respiratory and bloodstream sources: results from ACNBio study. Antimicrob Agents Chemother. 2025;69:e0037925.